CA2898431C - Compositions cellulaires issues de cellules reprogrammees dedifferenciees - Google Patents

Compositions cellulaires issues de cellules reprogrammees dedifferenciees Download PDF

Info

Publication number
CA2898431C
CA2898431C CA2898431A CA2898431A CA2898431C CA 2898431 C CA2898431 C CA 2898431C CA 2898431 A CA2898431 A CA 2898431A CA 2898431 A CA2898431 A CA 2898431A CA 2898431 C CA2898431 C CA 2898431C
Authority
CA
Canada
Prior art keywords
cells
cell
endoderm
heregulin
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2898431A
Other languages
English (en)
Other versions
CA2898431A1 (fr
Inventor
Alan D. Agulnick
Olivia Kelly
Yuki OHI
Allan Robins
Thomas Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Viacyte Inc filed Critical Viacyte Inc
Priority to CA3212301A priority Critical patent/CA3212301A1/fr
Publication of CA2898431A1 publication Critical patent/CA2898431A1/fr
Application granted granted Critical
Publication of CA2898431C publication Critical patent/CA2898431C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions de culture cellulaire, par exemple des compositions de culture cellulaire pancréatique, issues de cellules souches pluripotentes reprogrammées humaines dédifférenciées, telles que des cellules souches pluripotentes induites (iPS) et des procédés de production et d'utilisation de telles compositions de culture cellulaire.
CA2898431A 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees Active CA2898431C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3212301A CA3212301A1 (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 2013-02-06
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
PCT/US2014/015156 WO2014124172A1 (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammées dédifférenciées

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3212301A Division CA3212301A1 (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees

Publications (2)

Publication Number Publication Date
CA2898431A1 CA2898431A1 (fr) 2014-08-14
CA2898431C true CA2898431C (fr) 2023-10-17

Family

ID=50239931

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3212301A Pending CA3212301A1 (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees
CA2898431A Active CA2898431C (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3212301A Pending CA3212301A1 (fr) 2013-02-06 2014-02-06 Compositions cellulaires issues de cellules reprogrammees dedifferenciees

Country Status (8)

Country Link
EP (1) EP2954045A1 (fr)
JP (4) JP6517702B2 (fr)
AU (4) AU2014214879A1 (fr)
CA (2) CA3212301A1 (fr)
HK (1) HK1218139A1 (fr)
IL (4) IL290717B2 (fr)
RU (2) RU2754089C2 (fr)
WO (1) WO2014124172A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CA2957000C (fr) 2014-08-04 2023-08-01 Takeda Pharmaceutical Company Limited Procede de multiplication de cellules progenitrices pancreatiques
MA45479A (fr) * 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN109415680B (zh) * 2016-05-18 2022-08-16 学校法人庆应义塾 类器官培养用细胞培养基、培养方法及类器官
EP3587560A4 (fr) 2017-01-27 2020-12-16 Kaneka Corporation Masse cellulaire endodermique, et procédé de production d'une masse cellulaire quelconque parmi trois masses cellulaires de feuillet embryonnaire primaires à partir de cellules pluripotentes
CA3066055A1 (fr) 2017-06-14 2018-12-20 Semma Therapeutics, Inc. Dispositifs et methodes d'administration de substances therapeutiques
WO2020027316A1 (fr) * 2018-08-03 2020-02-06 国立大学法人京都大学 Procédé de production de cellules
BR112021004815A2 (pt) * 2018-09-19 2021-06-01 Takeda Pharmaceutical Company Limited células produtoras de insulina, medicamento, e, métodos para produzir células produtoras de insulina, para gerar células do tipo ilhota pancreática, para tratar diabetes mellitus, para melhorar e/ou manter o controle dos níveis de glicose em jejum e pós-prandial em um paciente e para reduzir o risco de hipoglicemia em um paciente com diabetes mellitus
JP2022535239A (ja) 2019-05-31 2022-08-05 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 生体適合性メンブレン複合体
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
AU2020283150B2 (en) 2019-05-31 2023-08-17 Viacyte, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
JP2022534545A (ja) 2019-05-31 2022-08-01 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 生体適合性メンブレン複合体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039160D1 (de) * 1999-04-06 2008-07-24 Genentech Inc Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US20040121460A1 (en) * 2001-01-24 2004-06-24 Lumelsky Nadya L Differentiation of stem cells to pancreatic endocrine cells
WO2007047509A2 (fr) * 2005-10-14 2007-04-26 Regents Of The University Of Minnesota Differenciation de cellules souches non-embryonnaires avec des cellules possedant un phenotype pancreatique
WO2007143193A1 (fr) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Cellules et tissu de l'endoderme pancréatique et hépatique obtenus par différenciation de cellules endodermiques définitives issues de cellules souches embryonnaires humaines
EP2356227B1 (fr) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation de cellules pancréatiques dérivées de cellules souches pluripotentes humaines
WO2010124142A2 (fr) * 2009-04-22 2010-10-28 Cythera, Inc. Compositions cellulaires issues de cellules reprogrammées dédifférenciées
SG10201401864VA (en) * 2009-04-27 2014-09-26 Viacyte Inc Small Molecules Supporting Pluripotent Cell Growth And Methods Thereof

Also Published As

Publication number Publication date
IL290717A (en) 2022-04-01
JP2020178694A (ja) 2020-11-05
AU2019201314B2 (en) 2021-10-14
RU2018144412A3 (fr) 2020-02-14
JP2019146578A (ja) 2019-09-05
EP2954045A1 (fr) 2015-12-16
CA2898431A1 (fr) 2014-08-14
HK1218139A1 (zh) 2017-02-03
IL283088A (en) 2021-06-30
RU2018144412A (ru) 2019-03-25
IL311689A (en) 2024-05-01
IL239953B (en) 2021-05-31
JP6517702B2 (ja) 2019-05-22
IL239953A0 (en) 2015-08-31
JP6721752B2 (ja) 2020-07-15
IL283088B (en) 2022-04-01
CA3212301A1 (fr) 2014-08-14
IL290717B1 (en) 2024-06-01
AU2022200075A1 (en) 2022-02-03
AU2014214879A1 (en) 2015-07-30
RU2675928C2 (ru) 2018-12-25
JP7250731B2 (ja) 2023-04-03
WO2014124172A1 (fr) 2014-08-14
RU2754089C2 (ru) 2021-08-26
IL290717B2 (en) 2024-10-01
RU2015131279A (ru) 2017-03-13
JP2016506736A (ja) 2016-03-07
AU2023202507A1 (en) 2023-05-11
JP7550830B2 (ja) 2024-09-13
AU2019201314A1 (en) 2019-03-14
AU2022200075B2 (en) 2023-02-02
JP2023017838A (ja) 2023-02-07
AU2022200075C1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US11905530B2 (en) Cell encapsulation device comprising a pancreatic progenitor cell population
AU2021266324B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
AU2022200075B2 (en) Cell compositions derived from dedifferentiated reprogrammed cells
EP2421957B1 (fr) Compositions cellulaires issues de cellules reprogrammées dédifférenciées

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206

EEER Examination request

Effective date: 20190206